Blueprint Medicines Corporation Profile Avatar - Palmy Investing

Blueprint Medicines Corporation

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (S…
Biotechnology
US, Cambridge [HQ]

Cash Flow Statements

11 Sheets · Starting from 2023
In Million USD. Margins, Growth Rates In %
Metric 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023
Operating Activities
Operating Cash Flow (OCF)
-19.00 -35.00 -31.00 -24.00 -119.00 -175.00 -278.00 387.00 -298.00 -502.00 -436.00
Operating Cash (Net)
-19.00 -35.00 -31.00 -24.00 -119.00 -175.00 -278.00 387.00 -298.00 -502.00 -436.00
Accounts Receivable
- - - - -3.00 - - 3.00 - - - - -6.00 -18.00 1.00 -7.00
Accounts Payable
- - - - 1.00 - - 1.00 - - 1.00 - - 4.00 -5.00 1.00
Working Capital
- - - - - - - - - - - - - - - - - - - - - -
Investing Activities
Used Cash (Net)
- - - - -6.00 -218.00 -75.00 -161.00 -16.00 -434.00 -225.00 -149.00 274.00
Capital Expenditure
- - - - -4.00 -2.00 -15.00 -12.00 -14.00 -3.00 -261.00 -8.00 -16.00
Purchases of Investments
- - - - -1.00 -264.00 -360.00 -801.00 -738.00 -969.00 -655.00 -489.00 -766.00
Sale/Maturity of Investment
- - - - - - 48.00 304.00 652.00 735.00 538.00 690.00 349.00 1,056.00
Property, Plant, Equipment (P&PE)
- - - - -4.00 -2.00 -15.00 -12.00 -14.00 -3.00 -261.00 -8.00 -16.00
Acquisitions (Net)
- - - - - - - - - - - - 2.00 431.00 258.00 - - - -
Other Investing Activities
- - - - -1.00 - - -3.00 -148.00 -2.00 -431.00 -258.00 - - - -
Financing Activities
Used Cash (Net)
-17.00 -81.00 -153.00 -132.00 -543.00 -4.00 -340.00 -617.00 -50.00 -561.00 -119.00
Debt Repayment
-3.00 - - -1.00 -3.00 -2.00 -1.00 - - - - - - -553.00 -97.00
Dividends Paid
- - - - - - - - - - - - - - - - - - - - - -
Common Stock
- - - - - - - - - - - - - - - - - - - - - -
Other Financing Activities
17.00 81.00 -2.00 135.00 - - - - 340.00 617.00 50.00 1,107.00 195.00
Cash Balances
Begin of Period
3.00 1.00 47.00 162.00 52.00 405.00 73.00 119.00 689.00 215.00 119.00
End of Period
1.00 47.00 162.00 52.00 400.00 73.00 119.00 689.00 215.00 124.00 71.00
Change
-1.00 45.00 115.00 -110.00 348.00 -331.00 46.00 570.00 -474.00 -90.00 -48.00
Non-Cash Balances
Depreciation and Amortization
- - - - - - 1.00 1.00 4.00 5.00 6.00 6.00 11.00 11.00
Stock Based Compensation
- - 2.00 5.00 6.00 12.00 - - 54.00 75.00 91.00 98.00 92.00
Other
- - - - - - - - - - -4.00 4.00 6.00 269.00 -1.00 -16.00
Highlighted metrics
Free Cash Flow (FCF)
-19.00 -36.00 -36.00 -26.00 -135.00 -187.00 -292.00 383.00 -559.00 -511.00 -452.00
Cash Conversion Cycle (CCC)
- - - - - - - - - - - - - - 3,628.00 349.00 618.00 309.00
Invested Capital
- - - - - - - - - - - - - - - - - - - - - -
Other Operating Inflows/Outflows
End of BPMC's Analysis
CIK: 1597264 CUSIP: 09627Y109 ISIN: US09627Y1091 LEI: - UEI: -
Secondary Listings
BPMC has no secondary listings inside our databases.